Zulato et al. prospectively enrolled advanced NSCLC patients carrying KRAS mutation and followed them with longitudinal liquid biopsy during treatment with chemotherapy (N = 39) and ICIs (N = 34) [65]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.